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Abstract
Background: The risk of cardiovascular disease is inversely correlated to level of plasma HDL-c. Moreover, reverse
cholesterol transport (RCT) from peripheral tissues to the liver is the most widely accepted mechanism linked to
the anti-atherosclerotic activity of HDL. The apolipoprotein A-I (apoA-I) and the ABC transporters play a key role in
this process.
Adipose tissue constitutes the body’s largest pool of free cholesterol. The adipose cell could therefore be regarded
as a key factor in cholesterol homeostasis. The present study investigates the capacity of primary cultures of
mature human adipocytes to release cholesterol and explores the relationships between apoA-I, ABCA1, and apoE
as well as the signaling pathways that could be potentially involved.
Results: We demonstrate that apoA-I induces a strong increase in cholesterol release and apoE secretion from
adipocytes, whereas it has no transcriptional effect on ABCA1 or apoE genes. Furthermore, brefeldin A (BFA), an
intracellular trafficking inhibitor, reduces basal cholesterol and apoE secretion, but does not modify induction by
apoA-I. The use of statins also demonstrates that apoA-I stimulated cholesterol release is independent of HMG-CoA
reductase activation.
Conclusion: Our work highlights the fact that adipose tissue, and particularly adipocytes, may largely contribute to
RCT via a mechanism specifically regulated within these cells. This further supports the argument that adipose
tissue must be regarded as a major factor in the development of cardiovascular diseases, in particular
atherosclerosis.
Background
Epidemiological studies have repeatedly highlighted a
strong inverse correlation between plasma concentra-
tions of high-density lipoprotein cholesterol (HDL-c)
and the risk of developing cardiovascular diseases, in
particular atherosclerosis, in humans. Thus, low levels of
plasma HDL-c increase the cardiovascular risk factor
[1]. Reverse cholesterol transport (RCT) from peripheral
tissues to the liver is a physiological process that enables
the negative regulation of cholesterol deposits via the
very low-density and low-density lipoprotein (VLDL and
LDL). During reverse transport, high-density lipopro-
teins (HDL) take up cholesterol from peripheral cells
and carry it to the liver. This process constitutes an
initial and crucial step in cholesterol homeostasis in
mammals, especially since cholesterol is cytotoxic when
present in excess quantity [2]. Moreover, the concept of
RCT from macrophages to the liver, and, ultimately to
biliary excretion sytem, is the most documented
mechanism to explain the ability of HDL to protect
against atherosclerosis.
RCT from peripheral cells to the liver is a multi-step
process. Initially, poorly lipidated apoA-I and small dis-
coidal shaped particles, preß-HDL, take up cholesterol
from peripheral cells. This results in a radical change,
giving rise to spherical HDL3 then HDL2 particles, due
to the fact that particles become enriched in esterified
cholesterol (via lecithin cholesterol acyl transferase
(LCAT) associated with preß-HDL particles) and phos-
pholipids. The final uptake of HDL2 by the liver involves
a selective receptor, the scavenger receptor B1 (SR-B1).
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tein, plays a critical role in RCT. The binding of apoA-I to
the ATP binding cassette transporter A1 (ABCA1) enables
transmembrane transport of free cholesterol and phospho-
lipids from peripheral cells into preß-HDL [3]. In addition,
apoA-I also stimulates the secretion of apolipoprotein E
(apoE); this action is probably partially dependent on
ABCA1 [4]. However, it’s well established that apoA-I,
apoE, and ABCA1 closely cooperate to optimize the cellu-
lar mobility of cholesterol that leads to the formation of
the HDLs [5]. ApoE plays a key role in this process, contri-
buting both to the efflux of cholesterol [5], and to the
expansion in the size of HDLs, by increasing the activity of
LCAT, which esterifies free cholesterol within the HDL
particles [6]. HDLs enriched in apoE (HDL1 or HDL-with
apoE) are also taken up by the liver via the apoB/apoE
LDL receptors (LDLR). In addition, Bernier et al, in colla-
boration with our laboratory, has demonstrated that over-
expression of apoE in adipocytes reduces differentiation as
well as the accumulation of cholesterol and triglycerides in
these cells [7]. These findings partly explain the strong
anti-atherogenic effect of this apoprotein.
The mechanisms involved in cholesterol efflux have
already been described with fundamental differences
related to the cell type studied. Indeed, it is known that
cAMP is able to stimulate the efflux of cholesterol in
murine macrophages and in RAW 264 cells [8,9],
whereas this effect is not detectable in human THP-1
cells or in human monocyte derived macrophages
[10,11]. Moreover, PKA activators (including cAMP) are
known to stimulate efflux,w h e r e a sP K Ai n h i b i t o r s
reduce efflux [12,13]. Finally, it is also known that PKC
activators are capable of activating cholesterol efflux in
fibroblasts, vascular smooth muscle cells, and in human
macrophages [14,15], whereas inhibitors of PKC lead to
a reduction in apoA-I induced efflux [16].
In addition, no data is currently available on the sig-
nalling pathways involved in the apoA-I induced secre-
tion of apoE.
Significantly, the vast majority of studies related to
RCT have used macrophage cell lines or primary cul-
tures loaded with cholesterol in vitro.H o w e v e r ,a d i p o s e
tissue is also capable of spontaneously accumulating
cholesterol and constitutes the most important storage
tissue of cholesterol in the human body. Adipocytes
may therefore be regarded as a “storage buffer”,w h i c h
may contribute to the regulation of plasma cholesterol.
We have therefore aimed to investigate the first step of
the RCT process, the cholesterol efflux, in primary cul-
tures of mature human adipocytes (full fat), and to
explore the relationships between apoA-I, ABCA1, and
apoE along different signaling pathways that may poten-
tially be involved in this process.
Methods
Materials
ApoA-I was purchased from Biomedical Technologies
Inc. (Stoughton, USA). Adenylate cyclase inhibitor (ACi)
was purchased from Calbiochem (USA). Rp-8-Br-cAMP,
PKA inhibitor (PKAi), brefeldin A (BFA) and forskolin
(FSK) were obtained from Clinisciences (Montrouge,
France). Simvastatin was purchased from Cayman (USA).
Origin of adipose tissue samples
Subcutaneous (abdominal, buttocks, hips and thighs)
tissue samples of human white fat were obtained from
normal weight or slightly overweight human subjects
(exclusively females, mean body mass index 24.23) under-
going liposuction, performed under general anesthesia, for
cosmetic reasons (aged between 25 and 60 years, mean
39 years). Apart from oral contraception, the subjects were
not receiving treatment with prescribed medication at the
time of liposuction. A total of 27 samples were obtained
from 27 patients. The study was approved by the Ile de La
Réunion ethics committee for the protection of persons
undergoing biomedical research.
Primary culture of human adipocytes
Cultures were prepared as previously described [17].
Briefly, tissue samples obtained by liposuction were
digested for 30 min at 37°C in Ringer-Lactate buffer con-
taining 1.5 mg/ml collagenase (NB5, SERVA, Germany,
PZ activity 0.131 U/mg). The floating adipocytes (mature
adipocytes) were rinsed three times in Ringer-Lactate.
Cells were plated in 24-well (30 000 cells) or 6-well (120
000 cells) tissue culture plates with 199 culture medium
supplemented with: 1% Fetal Bovine Serum (FBS) (PAN
Biotech, France), amphotericin B, (5 μg/mL), streptomy-
cin (0.2 mg/mL) & penicillin (200 U/mL) (PAN Biotech,
France), 66 nM insulin (Umuline Rapide, Lilly, France),
2g / Lg l u c o s e ,8μg/L biotin and 4 μg/mL pantothenate.
Cells were then maintained at 37°C in 5% CO2 for a per-
iod of 24 hours prior to the experiments.
Total cholesterol release
In the experiment to determine the apoA-I stimulated
total cholesterol release, cells were treated with apoA-I
(5, 10, 20 μg/ml) for 4, 6, 12 and 24 hours.
In inhibition experiments, mature adipocytes were
pre-incubated for 1 hour with PKAi (40 nM), rp-8-Br-
cAMP (40 μM) and ACi (20 μM). The medium was
removed and replaced with medium containing inhibi-
tors, with or without apoA-I (10 μg/ml) for 12 hours.
In the BFA and statin experiments, cells were pre-
incubated for 12 hours with BFA (5 μg/ml) and for 1
hour with simvastatin (10 and 100 nM). Medium was
removed and replaced with either medium alone or
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BFA and simvastatin were present throughout this incu-
bation time. Cell media were then collected and assayed
for cholesterol content with a Cayman’sC h o l e s t e r o l
Assay Kit according to the manufacturer’s instructions.
Quantification of intracellular cAMP stimulated by
forskolin
Cells were pre-incubated with ACi (20 μM) for 1 hour,
after which time the cell medium was changed. This
was then followed by a 30 min treatment with FSK (20
μM) and ACi (20 μM). After 30 min, adipocytes were
lysed with 0.1 M HCL and after dissociation and centri-
fugation, the cAMP was assayed in the supernatant by
the cAMP Direct Immunoassay Kit according to the
manufacturer’s instructions.
Quantification of apoE secretion by ELISA
In the apoA-I stimulated apoE experiment, cells were
treated with apoA1 dose response (5, 10, 20 μg/ml) for
6, 12 and 24 hours.
In the BFA (5 μg/ml) experiment, cells were pre-incu-
bated with BFA for 12 hours followed by BFA and with
or not apoA-I for 6 hours. Culture medium samples
were collected and assayed for apoE with The AssayMax
Human ApoE ELISA (Assaypro LLC, USA) according to
the manufacturer’s instructions.
RNA extraction, reverse transcription and real-time
quantitative PCR
Cells from 6 wells (3 × 10
5 cells) were extracted with 500
μLo fT R I z o l ™ reagent (Invitrogen, France). Total RNA
extraction was performed using the FastRNA® Pro Green
Kit (Qbiogene Ltd, France) according to the manufac-
turer’s instructions. Further mRNA purification was then
performed using TRIzol® Plus (Invitrogen). cDNA was
synthesized using the cDNA Synthesis System (Roche
Applied Science) and purified with a QIAquick PCR Pur-
ification Kit (QIAGEN, France). Real time qPCR was per-
formed using Taqman probes (ABI, Applied Biosystem
Instruments, France) according to the manufacturer’s
instructions. Gene expression analysis was performed
using a LightCycler480 RTqPCR cycler (Roche Applied
Science). Analysis was conducted using the Δ-Δcycle
threshold (ct) method, which determined fold changes in
gene expression relative to a control-treated sample.
Each analysis reaction was performed in duplicate, with 6
samples per condition. Gene expression was normalized
to glyceraldehyde-3-phosphate dehydrogenase (GAPDH),
which was used as an internal reference gene.
Statistical analysis
Statistical analysis was performed using Microsoft
Excel software. Differences were tested for significance
(P < 0.001, P < 0.01 and P < 0.05) by the unpaired Student’s
t-test.
Results
ApoA-I increases cholesterol release in mature human
adipocytes
It is widely accepted that apoA-I stimulates the efflux of
cholesterol in many cellular models. This has also been
demonstrated in murine adipocyte cell lines such as the
3T3-L1 [18], but to date there are no reports that a
study being conducted on primary cultures of human
adipocytes. Initially, we aimed to investigate the effect of
apoA-I. Figure 1 clearly shows that apoA-I increases in
a dose dependent manner the release of cholesterol
from mature human adipocyte cultures (panel A). We
have detected up to a 400% increase after 12 hours, with
this level sustained for up to 24 hours. Treatment of the
c e l l sw i t ha p o A - Id o e sn o tl e a dt oas i m u l t a n e o u s
increase in ABCA1 transcription (panel B).
ApoA-I induced cholesterol release is cAMP and PKA
independent
Previous studies have shown that apoA-I induces an
increase in ABCA1 phosphorylation, as well as an
increase in the intracellular levels of cAMP [19], sug-
gesting that the stimulatory effect of apoA-I could be
related to cAMP, and thus to PKA [12,13]. However, it
would appear that the results may be dependent upon
the species and the cellular model studied [20]. Figure 2
shows that treatment of adipocytes with forskolin leads
to an increase of intracellular cAMP, after 30 minutes of
treatment (panel A). This increase could be prevented
by the use of a specific adenylate cyclase inhibitor
(panel A). Conversely, the forskolin action does not
induce an increase in cholesterol secretion at 12 hours
(panel B). This finding was checked at 1, 2, 4 and 6
hours with no visible effect (data not shown). Moreover,
the use of specific PKA inhibitors (PKAi and Rp-8Br-
cAMP) or adenylate cyclase inhibitor does not lead to a
r e d u c t i o ni nt h ea c t i v a t o re ffect of apoA-I (panel C). It
should be noted that even the adipocyte basal release of
cholesterol is not modified by PKA or the adenylate
cyclase inhibitor.
Basal cholesterol release but not apoA-I stimulated
cholesterol release is inhibited by brefeldin A (BFA)
Numerous studies using different cell types have
demonstrated that brefeldin A (BFA) inhibits cholesterol
efflux [21,22]. In particular, Verghese et al. have demon-
strated in the murine adipocyte cell line, 3T3-L1, that
the basal efflux of cholesterol is very strongly inhibited
by BFA [22].
Given that well established differences between mur-
ine and human cells and between cell lines and primary
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on cholesterol release in mature human adipocytes.
Figure 3 clearly shows that in mature human adipo-
cytes, cholesterol release is sensitive to BFA. Indeed,
following treatment for 12 hours, BFA inhibits approxi-
mately 30% of the basal cholesterol release and 35% of
the apoA-I stimulated cholesterol release. In fact, the
reduction in cholesterol release observed during co-
treatment with BFA and apoA-I can be explained by the
effect on the basal release. Consequently, BFA has no
effect upon the apoA-I stimulated release of cholesterol.
ApoA-I induced cholesterol release is not linked to
cholesterol synthesis
In order to determine whether the apoA-I induced
efflux derives from a regulatory pool of cholesterol and
is therefore associated with an increase in HMG-CoA
reductase activity, we treated the adipocytes with a sta-
tin, which is a known inhibitor of this enzyme. Figure 4
shows that basal cholesterol release is strongly reduced
with simvastatin. Nevertheless, this statin has no effect
on cholesterol release. Surprisingly, no studies, as far as
we are aware, has yet investigated the direct effect of
statins on cholesterol release from human adipocytes.
ApoA-I increases apoE secretion with minimal effect upon
apoE gene expression
In addition to increasing cholesterol efflux, apoA-I is
known to activate apoE secretion, at least in macro-
phages. Figure 5 shows that a similar effect is also
clearly observed in adipocytes, since an increase of 100
to 500% in the amount of apoE is measured in the cul-
ture medium at 6 hours, dependent upon the dose of
apoA-I used (from 5 to 20 μg/ml). This effect is still
measurable up to 24 hours after treatment, although the
difference is no longer significant at this time point.
Importantly, under these conditions apoA-I does not
have a significant impact on apoE gene transcription
(panel B).
Brefeldin A inhibits basal apoE secretion but not apoA-I
induced apoE secretion
In order to clarify how apoA-I increased the adipocyte
secretion of apoE, we chose to use the Golgi secretion
inhibitor, BFA.
Figure 6 illustrates the effect of treating adipocytes
with apoA-I, BFA (5 μg/ml), or both together, at 6
hours, corresponding to the apoE secretion peak.
Whereas BFA effectively decreases the basal secretion of
apoE, the results obtained clearly reveal that BFA does
not affect apoA-I induced secretion of apoE.
Discussion
Numerous studies have shown that apoA-I is able to
activate cholesterol efflux as well as the secretion of
apoE [4,18,23]. However, most of these studies were
conducted on macrophages, rodent cell lines, or on dif-
ferentiated rabbit adipocytes. These studies have already
highlighted fundamental differences depending on the
cell type studied [20]. Moreover, given the major differ-
ences that exist between these various models and
Figure 1 ApoA-I stimulates total cholesterol release. Panel A:
Total cholesterol release was measured in the medium of mature
adipocytes treated or not with apoA-I (5, 10 or 20 μg/ml) at 4, 6, 12
and 24 hours by fluorometric dosage. The graph represents the
mean ± SD of the results from 4 patients (n = 6 for each condition,
for each patient) and all raw data has been normalised versus
control. ***P < 0.001%, **P < 0.01%, *P < 0.05%, versus untreated
cells. Panel B: ABCA1 gene expression was determined at 1.5, 3, 6
and 12 hours in mature adipocyte cultures, treated or not with
apoA-I (10 μg/ml). The graph represents the mean ± SD of the
results from one patient (n = 5 for each condition), representative
of two experiments on two different patients.
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very weak development of atherosclerotic processes, and
the absence of CETP in rodents [24], it seemed impor-
tant that the mechanisms of RCT in human adipose
tissue should be investigated.
Until recently, the studies that have been carried out
have used labelled cholesterol, enabling the detection of
cholesterol following secretion by the cell. This method
enables the detection of relatively small effects during
cholesterol secretion. The use of the human adipocyte
model means that cholesterol “loading” can be avoided,
since adipocytes produce and secrete sufficient basal
concentrations of cholesterol, with quantification possi-
ble via a simple fluorometric method. For this reason,
we talk about cholesterol release and not cholesterol
efflux, because the cells were not previously loaded with
exogenous cholesterol.
Our investigation clearly shows that apoA-I effectively
increases the release of cholesterol, as well as largely
increasing the secretion of apoE by mature adipocytes
(figures 1 and 5). These two concomitant effects most
probably contribute to the potentiation of the RCT via
Figure 2 ApoA-I induced cholesterol release is cAMP and PKA independent. Depending upon the conditions, mature adipocytes were pre-
treated or not for 1 hour with ACi (20 μM), PKAi (40 nM) or rp-8-Br-cAMP (40 μM). Cell medium was removed and cells were either treated or
not with ACi or PKAi, rp-8Br-cAMP, FSK (20 μM) and with or without apoA-I (10 μg/ml) for 30 min or 12 hours. Panel A: cAMP was quantified in
adipocytes, treated or not with ACi and FSK at 30 min, by competitive ELISA. Panel B: total cholesterol was measured in the medium of mature
adipocytes cultures, treated or not with ACi and FSK at 12 hours by fluorometric assay. Panel C: total cholesterol was measured in the medium
of mature adipocytes cultures, treated with different inhibitors and with or without apoA-I at 12 hours by fluorometric assay. Graphs represent
the mean ± SD of the results from 4 patients (n = 6 for each condition, for each patient) and all raw data has been normalised versus control.
***P < 0.001%, **P < 0.01% versus control cells and #P < 0.1% versus apoA-I treated cells.
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of apoE is crucial to the size increase of the HDLs [6]. It
is even more probable, that the presence of HDL1
(HDL-with apoE) has been underestimated until very
recently [25]. Indeed, the activation of apoE secretion by
apoA-I may not only lead to an optimum increase in
the size of the HDLs, but also to an increase in the
uptake of these particles by the liver via the apoB/E
LDLR according to the amount of apoE present.
Figure 3 Brefeldin A inhibits total cholesterol release in mature
human adipocytes. Mature adipocytes were pre-treated with BFA
(5 μg/ml) for 12 hours followed by treatment with or without apoA-
I (10 μg/ml). Total cholesterol was measured in the medium of
mature adipocytes cultures at 12 hours by fluorometric dosage. The
graph represents the mean ± SD of the results from 3 patients (n =
6 for each condition, for each patient) and all raw data has been
normalised versus control. ***P < 0.001% versus control cells and
###P < 0.001% versus apoA-I.
Figure 4 ApoA-I induced cholesterol release is not inhibited by
statins. Mature adipocytes were pre-treated with simvastatin (10
and 100 nM) for 1 hour followed by treatment with or without
apoA-I (10 μg/ml). Total cholesterol was measured in the medium
of mature adipocytes cultures at 12 hours by fluorometric dosage.
The graph represents the mean ± SD of the results from 3 patients
(n = 6 for each condition, for each patient) and all raw data has
been normalised versus control. *P < 0.05% versus control cells.
Figure 5 ApoA-I stimulates apoE secretion in mature human
adipocytes. Panel A: ApoE secretion was measured in the medium
of mature adipocytes cultures treated or not with apoA-I (5, 10 and
20 μg/ml) at 6, 12 and 24 hours by ELISA. The graph represents the
mean ± SD of the results from 4 patients (n = 6 for each condition,
for each patient). All raw data has been normalised versus control.
***P < 0.001%, versus control cells. Panel B: ApoE gene expression
was determined at 1.5, 3, 6 and 12 hours in mature adipocytes
cultures treated or not with apoA-I (10 μg/ml). The graph represents
the mean ± SD of the results from one patient (n = 5 for each
condition), representative of two experiments on two different
patients.
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mature adipocytes is concerned, we have highlighted
several major points.
First, the effect of apoA-I seems totally independent of
the increase in intracellular cAMP, since treatment of
the adipocytes with forskolin effectively leads to an
increase in the intracellular cAMP, but not to an
increase in cholesterol release (figure 2). Moreover,
treatment with PKA and adenylate cyclase inhibitors
does not lead to a reduction in apoA-I induced choles-
terol release (figure 2). This is in line with the results
obtained in other cellular models [20] showing that the
efflux of cholesterol from human macrophages is inde-
pendent of cAMP and PKA.
Secondly, the use of BFA inhibits basal cholesterol
release from adipocytes (figure 3). This finding concurs
with other studies to the effect that BFA partially or
completely inhibits basal cholesterol efflux [22]. The fact
that BFA disturbs intracellular vesicular trafficking, as
well as the dynamics and potentially the intracellular
distribution of ABCA1, suggests that BFA impacts the
rate of cholesterol efflux through its action on vesicular
transport. However, figure 3 clearly shows that BFA
does not modify the action of apoA-I on cholesterol
since an activator effect persists.
Thirdly, apoA-I does not induce an increase in extra-
cellular cholesterol by the activation of HMG-CoA
reductase since the use of specific inhibiting molecules
does not block the effect of the apoA-I (figure 4).
Nonetheless, it should be mentioned that the statins are
highly efficient on adipose cells, because after 24 hours
of treatment, the basal or apoA-I induced cholesterol
detected in the culture medium strongly decreases (data
not shown). Inhibition of HMG-CoA reductase by sim-
vastatin has no effect on the apoA-I induced release of
cholesterol (figure 4) suggesting that the increase in
cholesterol in the cell medium derives from a choles-
terol storage pool not related to a feed-back activation
of HMG-CoA reductase. The outcome is identical after
treatment with lovastatin (data not shown). However,
following 24 h treatment with the statins (data not
shown), concomitantly or not with apoA-I, the release
of cholesterol into the medium decreases significantly,
clearly demonstrating that the statins are active in adi-
pocytes, limit cholesterol formation in the cell, and thus
its release into the culture medium. This is definitely an
important result in that as far as we know, the role of
statins on adipocytes has never been investigated. This
suggests that clinical effects of statins are probably due,
at least in part, to their action within adipose tissue,
particularly in adipocytes.
The overall evidence collected suggests that the
increase in apoA-I induced cholesterol efflux is
mediated by a particular pathway in human adipocytes.
Certain studies clearly demonstrate that PKA plays a
key role in the phosphorylation of ABCA1 that leads to
its activation [19], whilst BFA disturbs vesicular traffic
as well as the intracellular distribution of ABCA1 [26].
However, our results prove that neither the inhibitors of
P K A ,n o rB F Aa r ea b l et od i s t u r bt h er e l e a s eo fa p o A - I
induced cholesterol. Moreover, this release is not linked
to the transcriptional regulation of the ABCA1 gene,
because apoA-I induced efflux does not lead to an
increase in ABCA1 gene expression (figure 1). This sug-
gests that the effect of the apoA-I is not directly linked
to the activation of ABCA1, or at least, that in adipo-
cyte, the activation of ABCA1 occurs through an unde-
scribed signaling pathway. In addition, treatment with
PKC activators and inhibitors does not modify the effect
of apoA-I (data not shown), whereas certain studies
have suggested the involvement of this pathway [20].
Therefore, this further supports the argument that a
particular and probably specific pathway in the adipo-
cyte does exist.
The regulation of apoE secretion by apoA-I, is neither
dependent upon an increase in gene transcription, nor
upon increased release from the Golgi (figures 5 and 6).
It may therefore be assumed that, in macrophage mod-
els, apoE is stored mainly in the cytoplasm and/or on
the cell surface, with apoA-I enabling secretion of this
cytoplasmic pool [4,23]. The same situation also seems
to occur in human adipocytes. Moreover, it is note-
worthy that inhibition of adenylate cyclase or PKA does
Figure 6 Brefeldin A inhibits basal apoE secretion but not the
apoA-I induced apoE secretion in mature human adipocytes.
Mature adipocytes were pre-treated with BFA (5 μg/ml) for 12 hours
and apoE secretion was measured in the medium of matures
adipocytes cultures treated or not with apoA-I (10 μg/ml) at 6 hours
by ELISA. The graph represents the mean ± SD of the results from 4
patients (n = 6 for each condition, for each patient). all raw data has
been normalised versus control.***P < 0.001% versus control cells,
###P < 0.001% versus apoA-I cells.
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tion (data not shown). This demonstrates that secretion
does not require an increase in intracellular cAMP nor
a PKA specific activation.
The apoE is highly implicated in the regulation of lipid
metabolism, in the expression of certain adipocyte
genes, and in the proliferation of pre-adipocytes
[7,27,28], with the secretion of apoE being controlled
during adipocyte differentiation [29]. We show here that
apoA-I strongly stimulates apoE secretion, suggesting
that in pathological conditions, such as obesity, the
combination of low HDL-c levels (carrying apoA-I) and
oxidative stress contributes to a major reduction in adi-
pocyte apoE secretion. This could lead to a reduced
apoE protective effect, during the development of adi-
pose tissue [7] and, in particular, during inflammation,
thus potentially leading to an increased risk of develop-
ing atherosclerosis.
In this regard, we recently demonstrated that mature
human adipocytes are able to secrete large quantities of
pro-inflammatory molecules such as IL-6 or TNFa [30].
There is therefore increasing evidence to support the
view that adipocytes are highly involved in the inflam-
matory phenomenon associated with the development of
obesity.
In addition, this tissue should no longer be considered
simply as a passive fatty-acid storage tissue since numer-
ous studies now demonstrate that it acts as a buffer
reservoir for circulating cholesterol [18,22]. Finally, the
interactions between pro- or anti-inflammatory mole-
cules and cholesterol efflux are now being highlighted
[31,32].
Conclusion
In conclusion, our work highlights the fact that adipose
tissue, particularly adipocytes, are key components of
the RCT in humans, and that this mechanism is without
doubt specifically regulated within these cells. Given
that HDL-c levels are reduced in patients that generally
have highly developed adipose tissue (obese and diabetic
individuals), we may argue that adipose tissue must be
regarded as a key contributing factor to the develop-
ment of cardiovascular diseases in particular athero-
sclerosis, in these patients.
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